Mainz Biomed (NASDAQ:MYNZ – Get Free Report) and AAR (NYSE:AIR – Get Free Report) are both industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.
Profitability
This table compares Mainz Biomed and AAR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mainz Biomed | N/A | N/A | N/A |
| AAR | 5.67% | 12.67% | 6.07% |
Valuation & Earnings
This table compares Mainz Biomed and AAR”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mainz Biomed | $659,935.00 | 20.18 | -$21.65 million | ($65.60) | -0.02 |
| AAR | $3.31 billion | 1.61 | $187.70 million | $4.83 | 27.70 |
AAR has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than AAR, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, AAR has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Mainz Biomed and AAR, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
| AAR | 0 | 2 | 4 | 1 | 2.86 |
AAR has a consensus price target of $135.60, suggesting a potential upside of 1.35%. Given AAR’s stronger consensus rating and higher probable upside, analysts plainly believe AAR is more favorable than Mainz Biomed.
Insider and Institutional Ownership
90.7% of AAR shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 3.1% of AAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
AAR beats Mainz Biomed on 13 of the 15 factors compared between the two stocks.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
About AAR
AAR Corp. provides products and services to commercial aviation, government, and defense markets worldwide. The Parts Supply segment leases and sells aircraft components and replacement parts. The Repair & Engineering segment provides airframe maintenance services, such as airframe inspection, painting, line maintenance, airframe modification, structural repair, avionics service and installation, exterior and interior refurbishment, and engineering and support services; component repair services comprising maintenance, repair, and overhaul (MRO) services, engine and airframe accessories, and interior refurbishment; and landing gear overhaul services, including repair services on wheels and brakes. This segment also develops specific aircraft components and parts; and designs proprietary designated engineering representative repairs. The Integrated Solutions segment engages in the fleet management and operation of customer-owned aircraft; provision of supply chain logistics services, such as material planning, sourcing, logistics, information and program management, and parts and component repair and overhaul services; and flight hour component inventory and repair services. In addition, the segment provides integrated software solutions comprising Trax, a cloud-based electronic enterprise resource platform, as well as a suite of paperless mobility apps for automating MRO workflows. The Expeditionary Services segment designs, manufactures, and repairs transportation pallets; and containers and shelters for military and humanitarian tactical deployment activities, including armories, supply and parts storage, refrigeration systems, tactical operation centers, briefing rooms, laundry and kitchen facilities, water treatment, and sleeping quarters, as well as engages in provision of engineering, design, and system integration services for specialized command and control systems. AAR Corp. was founded in 1951 and is headquartered in Wood Dale, Illinois.
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
